SE465352B - Anvaendning av diltiazem foer framstaellning av ett laekemedel foer behandling av hyperlipidemi - Google Patents
Anvaendning av diltiazem foer framstaellning av ett laekemedel foer behandling av hyperlipidemiInfo
- Publication number
- SE465352B SE465352B SE8403042A SE8403042A SE465352B SE 465352 B SE465352 B SE 465352B SE 8403042 A SE8403042 A SE 8403042A SE 8403042 A SE8403042 A SE 8403042A SE 465352 B SE465352 B SE 465352B
- Authority
- SE
- Sweden
- Prior art keywords
- diltiazem
- hyperlipidemia
- treatment
- medicine
- preparation
- Prior art date
Links
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims description 3
- 229960004166 diltiazem Drugs 0.000 title description 7
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 title description 7
- 238000002360 preparation method Methods 0.000 title description 3
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 229960005316 diltiazem hydrochloride Drugs 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 235000019759 Maize starch Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- HDRXZJPWHTXQRI-BHDTVMLSSA-N diltiazem hydrochloride Chemical compound [Cl-].C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CC[NH+](C)C)C2=CC=CC=C2S1 HDRXZJPWHTXQRI-BHDTVMLSSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- KOWWOODYPWDWOJ-LVBPXUMQSA-N elatine Chemical compound C([C@]12CN(C3[C@@]45OCO[C@]44[C@H]6[C@@H](OC)[C@@H]([C@H](C4)OC)C[C@H]6[C@@]3([C@@H]1[C@@H]5OC)[C@@H](OC)CC2)CC)OC(=O)C1=CC=CC=C1N1C(=O)CC(C)C1=O KOWWOODYPWDWOJ-LVBPXUMQSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- -1 inorganic acid salts Chemical class 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58104691A JPS59231018A (ja) | 1983-06-10 | 1983-06-10 | 抗脂血剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8403042D0 SE8403042D0 (sv) | 1984-06-06 |
| SE8403042L SE8403042L (sv) | 1984-12-11 |
| SE465352B true SE465352B (sv) | 1991-09-02 |
Family
ID=14387491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8403042A SE465352B (sv) | 1983-06-10 | 1984-06-06 | Anvaendning av diltiazem foer framstaellning av ett laekemedel foer behandling av hyperlipidemi |
Country Status (12)
| Country | Link |
|---|---|
| JP (1) | JPS59231018A (en)) |
| BE (1) | BE899867A (en)) |
| CH (1) | CH661867A5 (en)) |
| DE (1) | DE3419425A1 (en)) |
| DK (1) | DK164021C (en)) |
| FR (1) | FR2547730B1 (en)) |
| GB (1) | GB2141027B (en)) |
| HK (1) | HK45489A (en)) |
| IT (1) | IT1196710B (en)) |
| NL (1) | NL8401793A (en)) |
| SE (1) | SE465352B (en)) |
| SG (1) | SG21089G (en)) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4778791A (en) * | 1986-05-16 | 1988-10-18 | Tanabe Seiyaku Co., Ltd. | Pharmaceutical composition for improving constitution of lipids in blood |
| JPS63107925A (ja) * | 1986-05-23 | 1988-05-12 | Tanabe Seiyaku Co Ltd | 動脈硬化症予防・治療剤 |
| AT389446B (de) * | 1987-10-08 | 1989-12-11 | Tanabe Seiyaku Co | Verwendung eines 8-chlorobenzothiazepins zur herstellung eines arzneimittels |
| DE3737741A1 (de) * | 1987-11-06 | 1989-05-18 | Goedecke Ag | Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid |
| GB9423172D0 (en) * | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3562257A (en) * | 1967-10-28 | 1971-02-09 | Tanabe Seiyaku Co | Benzothiazepine derivatives |
| JPS58208222A (ja) * | 1982-05-28 | 1983-12-03 | Japan Found Cancer | 抗腫瘍剤効果増強剤 |
| JPS5970611A (ja) * | 1982-10-15 | 1984-04-21 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
-
1983
- 1983-06-10 JP JP58104691A patent/JPS59231018A/ja active Granted
-
1984
- 1984-05-24 DE DE19843419425 patent/DE3419425A1/de active Granted
- 1984-06-05 NL NL8401793A patent/NL8401793A/nl not_active Application Discontinuation
- 1984-06-06 SE SE8403042A patent/SE465352B/sv not_active IP Right Cessation
- 1984-06-07 GB GB08414498A patent/GB2141027B/en not_active Expired
- 1984-06-08 IT IT67596/84A patent/IT1196710B/it active
- 1984-06-08 DK DK284084A patent/DK164021C/da not_active IP Right Cessation
- 1984-06-08 FR FR8409077A patent/FR2547730B1/fr not_active Expired
- 1984-06-08 BE BE0/213101A patent/BE899867A/fr not_active IP Right Cessation
- 1984-06-12 CH CH2838/84A patent/CH661867A5/de not_active IP Right Cessation
-
1989
- 1989-04-07 SG SG210/89A patent/SG21089G/en unknown
- 1989-06-07 HK HK454/89A patent/HK45489A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IT8467596A0 (it) | 1984-06-08 |
| NL8401793A (nl) | 1985-01-02 |
| GB2141027B (en) | 1986-10-22 |
| DE3419425C2 (en)) | 1989-06-08 |
| FR2547730A1 (fr) | 1984-12-28 |
| IT1196710B (it) | 1988-11-25 |
| DK164021B (da) | 1992-05-04 |
| GB2141027A (en) | 1984-12-12 |
| DK164021C (da) | 1992-09-28 |
| DK284084A (da) | 1984-12-11 |
| SG21089G (en) | 1990-01-26 |
| HK45489A (en) | 1989-06-16 |
| SE8403042L (sv) | 1984-12-11 |
| SE8403042D0 (sv) | 1984-06-06 |
| CH661867A5 (de) | 1987-08-31 |
| DK284084D0 (da) | 1984-06-08 |
| JPS59231018A (ja) | 1984-12-25 |
| IT8467596A1 (it) | 1985-12-08 |
| GB8414498D0 (en) | 1984-07-11 |
| JPS6317810B2 (en)) | 1988-04-15 |
| DE3419425A1 (de) | 1984-12-13 |
| FR2547730B1 (fr) | 1987-11-13 |
| BE899867A (fr) | 1984-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4255449A (en) | Method of treating abnormal lipoprote in ratios | |
| DE3879080T2 (de) | Pharmazeutische matrix mit verzoegerter freisetzung und verfahren. | |
| US4268524A (en) | Method of treating abnormal lipoprotein ratios with acylcarnitine | |
| SK2612002A3 (en) | Pharmaceutical formulation containing benzamide derivative with improved solubility and oral absorptivity | |
| SE465352B (sv) | Anvaendning av diltiazem foer framstaellning av ett laekemedel foer behandling av hyperlipidemi | |
| US3144387A (en) | Anti-inflammatory compositions | |
| AU666992B2 (en) | Pharmaceutical composition for preventing or treating arteriosclerosis | |
| KR860006265A (ko) | 9,10-디하이드로 에르고트 알카로이드를 함유하는 서방성 제재의 제조방법 | |
| FI89004B (fi) | Anvaendning av tillsatsmedel foer oekning av absorptionshastigheten av laekemedel i orala laekemedelspreparat | |
| EP0600582A1 (en) | Treatment for muscular dystrophy | |
| RU2141314C1 (ru) | Противовирусный препарат "амиксин" и способ его получения | |
| US4083994A (en) | Choleretics | |
| CN102552210B (zh) | 一种恩替卡韦胶囊组合物及其制备方法 | |
| JPS5938207B2 (ja) | 腎疾患治療剤 | |
| US4311694A (en) | Amorphous coprecipitates of 4-(monoalkylamino) benzoic acid and derivatives and certain water-soluble materials | |
| RU2002115814A (ru) | Лечение системной красной волчанки с помощью дегидроэпиандростерона | |
| JPS58140017A (ja) | 心不全治療剤 | |
| JPS6137731A (ja) | グアバ葉エキスを有効成分とする経口糖尿病薬 | |
| JP3186365B2 (ja) | 肝疾患治療薬 | |
| Upadhyay et al. | Studies on Formulation and optimization of Gastro Retentive multi-Particulates of Glibenclamide and Metformin hydrochloride for the treatment of Type II Diabetes mellitus using Gelucire: A Review | |
| JPWO2004096230A1 (ja) | 関節リウマチ治療剤 | |
| Calanchi et al. | Pharmaceutical applications of microencapsulation using coacervation/phase separation techniques | |
| EP1941910A1 (en) | Pharmaceutical form for the treatment of patients with acute cases and exacerbations of rheumatoid arthritis and related acute disorders | |
| JPH03232870A (ja) | チオアミド化合物 | |
| JPH03287531A (ja) | 膵炎治療薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 8403042-8 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 8403042-8 Format of ref document f/p: F |